canopy-a: canakinumab for resected nsclc
Published 3 years ago • 200 plays • Length 1:30Download video MP4
Download video MP3
Similar videos
-
3:37
canopy-a: canakinumab for early stage nsclc
-
6:22
refining which patients benefit from consolidation durvalumab for stage iii unresectable nsclc
-
1:28
durvalumab as a consolidation therapy for locally advanced nsclc
-
3:39
what is durvalumab’s future as a treatment option in lung cancer?
-
2:23
therapeutic strategies for egfr-mutated lung cancer
-
1:10
future targets for pancreatic cancer treatment
-
1:46
the evolving treatment landscape for nsclc with egfr exon 20 insertion mutations
-
1:11
highlights from aacr 2021
-
1:14
destiny-lung01: a practice-changing trial for nsclc
-
1:36
efficacy of datopotamab deruxtecan, a trop2 adc, in ansclc
-
1:07
pacific trial updates: durvalumab after chemotherapy in nsclc
-
6:48
durvalumab improves pfs in stage iii lung cancer
-
3:48
lung cancer screening
-
1:44
post-hoc subgroup analysis from pacific: durvalumab after crt in unresectable stage iii egfrm nsclc
-
1:01
canopy cancer care patient orientation overview
-
2:13
future directions for lung cancer research
-
1:04
where can i receive further information on lung cancer? | lung foundation australia
-
1:38
practical considerations for durvalumab in stage 3 nsclc
-
5:28
durvalumab consolidation in nsclc: the pacific trial